Retrospective Study of Sequential Therapy with Afatinib Followed by Osimertinib in EGFR Mutation-Positive NSCLC
A global, non-interventional chart review based on existing medical records of patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC) who were treated with first-line afatinib,* developed the T790M mutation and were then treated with second-line osimertinib.1,2
Trial CT.gov-Identifier: NCT033707703
The patient population included a range of ethnicities with 120 (59%) Caucasian patients, 50 (25%) Asian patients and 18 (9%) African-American patients.1-2 At the start of afatinib treatment, Eastern Cooperative Oncology Group performance status (ECOG PS) was 0/1 in 152 (75%) patients and ≥2 in 31 (15%) patients.2One hundred and forty-nine (73%) patients had a Del19 mutation, 53 (26%) had the L858R mutation and 21 (10%) had stable brain metastases.2
At the time of the final analysis (December 2019), median follow-up was 33.9 months.2 Median OS was 37.6 months (90% confidence interval [CI]: 35.5–41.3) in the overall patient population, 44.8 months (90% CI: 37.0‒57.8) in Asian patients, and 41.6 months (90% CI: 36.9‒45.0) in patients with the Del19 EGFR mutation.2 The 2-year OS rate from the start of afatinib treatment was 80% in the overall patient population, 90% in Asian patients, and 84% in patients with Del19-positive tumors.2
Clinical benefit of sequential afatinib and osimertinib was also observed across patient subgroups often excluded from clinical trials. Median OS was 31.0 months in patients with brain metastases, 36.9 months in patients aged ≥65 years, and 32.0 months in those with ECOG PS ≥2.2
Overall survival in patients treated with sequential afatinib and osimertinib2
CI, confidence interval; OS, overall survival.
Time on treatment
The median overall time on sequential afatinib and osimertinib treatment was 27.7 months (90% CI: 26.7–29.9) in the overall patient population, 37.1 months in Asian patients (90% CI: 28.1–40.3), and 30.0 months (90% CI: 27.6–31.9) in patients with Del19-positive tumors.2
Clinical benefit was also consistent in patients with poor prognostic characteristics: median time on treatment was 22.2 months in patients with brain metastases, 27.3 months in patients aged ≥65 years, and 22.2 months in those with ECOG PS ≥2.2
Time on treatment with sequential afatinib and osimertinib2
CI, confidence interval.
Mutational status after osimertinib discontinuation
In the initial analysis (database lock: June 2018), data on tumor mutation profile in terms of either EGFR sensitizing mutations and/or T790M were only available from 39 of the 106 patients who had discontinued osimertinib.1 Although mutation data after osimertinib discontinuation had been explicitly requested, no mutations other than common EGFR mutations (Del19/L858R) and/or T790M were reported.1
The main limitations of the GioTag study were its retrospective nature, the lack of a comparator arm, and the potential for selection bias by excluding patients who died after first-line afatinib treatment or under-representing patients who derived long-term benefit from first-line afatinib treatment.2
The final results of this international, observational study suggest that sequential afatinib followed by osimertinib can be a feasible and effective therapeutic strategy in real-world patients with EGFR mutation-positive NSCLC who develop T790M.2
Of note, median OS was over 3.5 years in Asian patients and patients with Del19-positive tumors, suggesting that sequential use of tyrosine kinase inhibitors could potentially allow these EGFR mutation-positive NSCLC patients to receive long-term, chemotherapy-free treatment.2
Importantly, the clinical benefit was consistent across patients with poor prognostic characteristics.2 For example, patients with ECOG PS ≥2 and stable brain metastases also appeared to derive clinical benefit.2
Molecular testing following progression on osimertinib was limited, which may reflect the lack of approved treatments in this setting.1
Overall, these data suggest that sequential afatinib followed by osimertinib can be a feasible and effective therapeutic strategy in real-world patients with EGFR mutation-positive NSCLC who develop T790M, particularly in Asian patients and patients with Del19-positive tumors.2
Hochmair MJ, et al. Future Oncol 2018;14(27):2861–7.
Hochmair MJ, et al. Future Oncol 2020;16(34):2799–808.
Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT03370770 (Accessed: January 2021).
*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.
© 2021 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: January 2021
Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.
Do you want to continue ?Continue